Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Sponsor: Terumo BCT
Listed as NCT01736657, this NA trial focuses on Sickle Cell Disease and remains completed. Sponsored by Terumo BCT, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Terumo BCT
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Aurora, United States
- • Baltimore, United States
- • Birmingham, United States
- • Louisville, United States
- • Oakland, United States